Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Immuno-oncology is a unique medical approach to treating cancer that utilizes the body's own immune system to fight off cancer cells.
We’re committed to developing pelareorep into an effective treatment that can be combined with multiple therapies in order to boost its mechanism of action response.
Taking advantage of stressed tumor cells to initiate cell lysis.
An approach, and collaboration opportunity, where pelareorep is combined with immunotherapies (such as with Keytruda®, Opdivo® and Tecentriq®).
Pelareorep is currently being studied in combination with Celgene's Imnovid® & Revlimid® in a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma.
Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA
Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference